ArticleJournal of proteome research2012
Improving international research with clinical specimens: 5 achievable objectives.
Article in Journal of proteome research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Recommendations for cellular and molecular pathology input into clinical trials: a systematic review and meta-aggregation.The journal of pathology. Clinical research · 2021Pooled it
- Proteomic changes induced by longevity-promoting interventions in mice.GeroScience · 2024Article
- Building Research Support Capacity across Human Health Biobanks during the COVID-19 Pandemic.Biomarker insights · 2021Article
- Metabolomics technology and bioinformatics for precision medicine.Briefings in bioinformatics · 2019Review
- What's in a sample? Increasing transparency in biospecimen procurement methods.Nature methods · 2018Article
- Measuring myokines with cardiovascular functions: pre-analytical variables affecting the analytical output.Annals of translational medicine · 2017Review
- Novel bone metabolism-associated hormones: the importance of the pre-analytical phase for understanding their physiological roles.Endocrine · 2017Review
- A critical analysis of cancer biobank practices in relation to biospecimen quality.Biophysical reviews · 2015Review
- Proteomics analysis of bodily fluids in pancreatic cancer.Proteomics · 2015Review
- Pre-analytical sample quality: metabolite ratios as an intrinsic marker for prolonged room temperature exposure of serum samples.PloS one · 2015Article
- Elevated plasma albumin and apolipoprotein A-I oxidation under suboptimal specimen storage conditions.Molecular & cellular proteomics : MCP · 2014Article
- Standardization developments for large scale biobanks in smoking related diseases - a model system for blood sample processing and storage.Translational respiratory medicine · 2013Article
- Establishing a Southern Swedish Malignant Melanoma OMICS and biobank clinical capability.Clinical and translational medicine · 2013Article
- BioBanking as the central tool for translational medicine CTM issue 2013.Clinical and translational medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Our increased interest in translational research has created a large demand for blood, tissue, and other clinical samples, which find use in a broad variety of research including genomics, proteomics, and metabolomics. Hundreds of millions of dollars have been invested internationally on the collection, storage, and distribution of samples. Nevertheless, many researchers complain in frustration about their inability to obtain relevant and/or useful samples for their research. Lack of access to samples, poor condition of samples, and unavailability of appropriate control samples have slowed our progress in the study of diseases and biomarkers. In this perspective, I focus on five major challenges that thwart clinical sample use for translational research and propose near term objectives to address them. They include: (1) defining our biobanking needs; (2) increasing the use of and access to standard operating procedures; (3) mapping interobserver differences for use in normalizing diagnoses; (4) identifying natural internal protein controls; and (5) redefining the clinical sample paradigm by building partnerships with the public. In each case, I believe that we have the tools at hand required to achieve the objective within 5 years. Potential paths to achieve these objectives are explored. However we solve these problems, the future of proteomics depends on access to high quality clinical samples, collected under standardized conditions, accurately annotated and shared under conditions that promote the research we need to do.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.